<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1884909/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Enantioselective disposition of lansoprazole in relation to
CYP2C19 genotypes in the presence of fluvoxamine</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1884909/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine" />
<meta name="citation_authors" content=
"Masatomo Miura, Hitoshi Tada, Norio Yasui-Furukori, Tsukasa Uno, Kazunobu Sugawara, Tomonori Tateishi, Toshio Suzuki" />
<meta name="citation_date" content="July 2005" />
<meta name="citation_issue" content="1" />
<meta name="citation_volume" content="60" />
<meta name="citation_firstpage" content="61" />
<meta name="citation_doi" content=
"10.1111/j.1365-2125.2005.02381.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1884909/?report=abstract" />
<meta name="citation_pmid" content="15963095" />
<meta name="DC.Title" content=
"Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Masatomo Miura" />
<meta name="DC.Contributor" content="Hitoshi Tada" />
<meta name="DC.Contributor" content="Norio Yasui-Furukori" />
<meta name="DC.Contributor" content="Tsukasa Uno" />
<meta name="DC.Contributor" content="Kazunobu Sugawara" />
<meta name="DC.Contributor" content="Tomonori Tateishi" />
<meta name="DC.Contributor" content="Toshio Suzuki" />
<meta name="DC.Date" content="2005 Jul" />
<meta name="DC.Identifier" content=
"10.1111/j.1365-2125.2005.02381.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"Lansoprazole is affected by polymorphism of CYP2C19. The aim of this study was to examine the effects of fluvoxamine, a CYP2C19 inhibitor, on the pharmacokinetics of each lansoprazole enantiomer among three different CYP2C19 genotype groups.Eighteen healthy ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884909/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1884909/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1884909/pdf/bcp0060-0061.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FB704F6FE7D121000000000069E096" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/144695/">v.60(1); 2005 Jul</a></li>
<li class="accid">PMC1884909</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2005 Jul; 60(1):
61–68.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1111%2Fj.1365-2125.2005.02381.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1111/j.1365-2125.2005.02381.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1884909</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Enantioselective disposition of
lansoprazole in relation to <em>CYP2C19</em> genotypes in the
presence of fluvoxamine</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Miura%20M%5Bauth%5D">Masatomo Miura</a>,<sup>1</sup>
<a href="/pubmed/?term=Tada%20H%5Bauth%5D">Hitoshi
Tada</a>,<sup>1</sup> <a href=
"/pubmed/?term=Yasui-Furukori%20N%5Bauth%5D">Norio
Yasui-Furukori</a>,<sup>2</sup> <a href=
"/pubmed/?term=Uno%20T%5Bauth%5D">Tsukasa Uno</a>,<sup>3</sup>
<a href="/pubmed/?term=Sugawara%20K%5Bauth%5D">Kazunobu
Sugawara</a>,<sup>3</sup> <a href=
"/pubmed/?term=Tateishi%20T%5Bauth%5D">Tomonori
Tateishi</a>,<sup>2</sup> and <a href=
"/pubmed/?term=Suzuki%20T%5Bauth%5D">Toshio
Suzuki</a><sup>1</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id413468_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>Department of Pharmacy,
Akita University Hospital, Akita</div>
<div class="fm-affl" lang="en"><sup>2</sup>Department of Clinical
Pharmacology, Hirosaki University School of Medicine,
Hirosaki</div>
<div class="fm-affl" lang="en"><sup>3</sup>Department of Pharmacy,
Hirosaki University Hospital, Hirosaki, Japan</div>
<div id="cor1">Correspondence: Toshio Suzuki, PhD, Department of
Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010–8543,
Japan. Tel: + 81 1883 41111 Fax: + 81 1883 62628 E-mail: <a href=
"mailto:dev@null" data-email="pj.ca.u-atika.soh@ikuzus" class=
"oemail">pj.ca.u-atika.soh@ikuzus</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id413468_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id413468_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id413468_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id413468_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 2004 Aug 12; Accepted
2004 Nov 2.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id413468_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2005 Blackwell
Publishing Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC1884909/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid418590" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid418590title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">Lansoprazole is affected by
polymorphism of CYP2C19. The aim of this study was to examine the
effects of fluvoxamine, a CYP2C19 inhibitor, on the
pharmacokinetics of each lansoprazole enantiomer among three
different <em>CYP2C19</em> genotype groups.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">Eighteen healthy subjects, of
whom six each were homozygous extensive metabolizers (homEMs),
heterozygous extensive metabolizers (hetEMs), or poor metabolizers
(PMs) for CYP2C19, participated in the study. Each subject received
either placebo or fluvoxamine, 25 mg twice daily for 6 days, then a
single oral dose of 60 mg of racemic lansoprazole. The plasma
concentrations of lansoprazole enantiomers and lansoprazole
sulphone were subsequently measured for 24 h post lansoprazole
administration using liquid chromatography.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">In the homEMs and hetEMs,
fluvoxamine significantly increased the AUC(0, ∞) and
<em>C</em><sub>max</sub> and prolonged the elimination half-life of
both (R)- and (S)-lansoprazole, whereas in the PMs, the only
statistically significant effect of fluvoxamine was on the AUC(0,
∞) for (R)-lansoprazole. The mean fluvoxamine-mediated percent
increase in the AUC(0, ∞) of (R)-lansoprazole in the homEMs
compared with the PMs was significant (<em>P =</em> 0.0117);
however, <em>C</em><sub>max</sub> did not differ among the three
<em>CYP2C19</em> genotypes. On the other hand, fluvoxamine induced
a significant percent increase in both the AUC(0, ∞) and
<em>C</em><sub>max</sub> for (S)-lansoprazole in the homEMs
compared with the hetEMs (<em>P</em> = 0.0007 and <em>P</em> =
0.0125, respectively) as well as compared with the PMs (<em>P</em>
&lt; 0.0001 for each parameter). The mean R : S ratio for AUC(0, ∞)
of lansoprazole in the homEMs was significantly different between
the placebo and the fluvoxamine treatment groups (12.7 (9.1, 16.8)
<em>vs</em> 6.4 (5.4, 7.4), respectively, <em>P</em> &lt; 0.0001),
though not in the PMs (5.5 (4.3, 6.7) <em>vs</em> 5.9 (5.3, 6.5),
respectively).</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">The magnitude of the
contribution of CYP2C19 to the metabolism of (S)-lansoprazole is
much greater compared with that of the (R)-enantiomer. In extensive
metabolizers, hepatic CYP2C19 plays an important role in the
absorption and elimination of lansoprazole, particularly the
(S)-enantiomer.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">CYP2C19, enantiomer, fluvoxamine,
lansoprazole</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Lansoprazole is a proton pump
inhibitor (PPI) that inhibits gastric acid secretion by interacting
with (H<sup>+</sup>/K<sup>+</sup>)-ATPase in gastric parietal cells
[<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137252380">1</a>
This drug is extensively metabolized by CYP2C19 and CYP3A4 to two
major plasma metabolites, 5-hydroxylansoprazole and lansoprazole
sulphone, respectively [<a href="#b2" rid="b2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252397">2</a>–<a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252385">4</a>]. The CYP2C19-catalyzed hydroxylation
pathway is the main disposition route of lansoprazole and hence,
the disposition of lansoprazole is strongly influenced by CYP2C19
genetic polymorphism [<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137252386">5</a>,
<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252395">6</a>].</p>
<p id="__p6">Lansoprazole is administered clinically as a racemic
mixture of the (R)- and (S)-enantiomers. It has been reported that
the plasma concentrations of (R)-lansoprazole are higher than those
of the (S)-enantiomer following an oral dose of 30 mg of racemic
lansoprazole in both extensive metabolizers (EMs) and poor
metabolizers (PMs) [<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252393">7</a>]. The differences between the
pharmacokinetics of lansoprazole enantiomers are assumed to be
influenced by enantioselective metabolism [<a href="#b8" rid="b8"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252388">8</a>, <a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252383">9</a>]. Kim <em>et al</em>. reported that the
affinity and the intrinsic clearance for CYP2C19 catalyzed
5-hydroxylation of (S)-lansoprazole is higher than for the
(R)-enantiomer [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252392">8</a>]. Therefore, one can expect that the
disposition of (S)-lansoprazole is more intensely affected by
CYP2C19 polymorphism than that of the (R)-enantiomer. Fluvoxamine,
a selective serotonin reuptake inhibitor (SSRI), is a known potent
CYP1A2 inhibitor and it also inhibits CYP2C19 [<a href="#b10" rid=
"b10" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252381">10</a>, <a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252400">11</a>]. Thus when lansoprazole is administered
in the presence of fluvoxamine, one can assume a resultant increase
in the plasma concentration of (S)-lansoprazole compared with that
of the (R)-enantiomer.</p>
<p id="__p7" class="p p-last">On the basis of the above-described
background and hypothesis, we investigated the effect of
fluvoxamine on the disposition of lansoprazole enantiomers in
relation to the <em>CYP2C19</em> genotype status.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p8" class="p p-first-last">Eighteen healthy Japanese
subjects (homozygous extensive metabolizer group (homEMs,
<em>n</em> = 6), heterozygous extensive metabolizer group (hetEMs,
<em>n</em> = 6) and poor metabolizer group (PMs, <em>n</em> = 6))
were selected to participate in this study. The subjects enrolled
in the present study are the same as those who participated in our
previous study [<a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252384">12</a>]. The mean age was 25.1 ± 3.8 years (range
21–34 years) and the mean weight was 56.6 ± 13.3 kg (range 40–86
kg). There were no differences among the three <em>CYP2C19</em>
genotypes (homEMs, hetEMs and PMs) with respect to age (24.7 ± 3.8,
25.0 ± 4.5 and 25.7 ± 3.6 years, respectively), body weight (57.2 ±
15.6, 53.0 ± 10.5 and 59.5 ± 15.0 kg, respectively), body mass
index (20.9 ± 3.8, 20.5 ± 2.5 and 21.3 ± 3.5 kg m<sup>−2</sup>,
respectively) and male : female ratios (3 : 3 in each group)
[<a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252398">12</a>]. None of the subjects had a history of
significant medical illness or hypersensitivity to any drug nor
were any of the subjects smokers. The study protocol was approved
by the ethics committee of Hirosaki University Hospital, and all
subjects gave their written informed consent prior to study
participation.</p>
</div>
<div id="__sec8" class="sec">
<h3>Study protocol</h3>
<p id="__p9" class="p p-first-last">A randomized double-blind
placebo-controlled crossover study design was conducted at
intervals of 2 weeks. After fluvoxamine (25 mg) in capsule form
containing a tablet (Luvox®, Fujisawa Pharmaceutical Co., Ltd,
Osaka, Japan) or matched placebo (in capsule form with the same
appearance and size as that of fluvoxamine) was given orally twice
a day (09.00 h, 21.00 h) for 6 days, each subject received an oral
dose of 60 mg of lansoprazole (Takepron®, Takeda Pharmaceutical Co.
Ltd, Osaka, Japan) with 240 ml of tap water at 09.00 h. Venous
blood samples were taken before lansoprazole administration and
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the drug was taken to
measure the plasma concentration of lansoprazole enantiomers and
lansoprazole sulphone. The samples were centrifuged at 3000
<em>g</em> immediately after collection and stored at −80°C until
analysis. All subjects fasted for 10 h before the administration of
lansoprazole and had a standard meal 4 h later. Alcohol and
caffeinated beverages were forbidden during the study period.</p>
</div>
<div id="__sec9" class="sec">
<h3>CYP2C19 <em>genotyping</em></h3>
<p id="__p10" class="p p-first-last">The genotyping procedure used
to identify the <em>CYP2C19</em> wild-type gene and its two mutant
alleles, <em>CYP2C19*2</em> in exon 5 and <em>CYP2C19*3</em> in
exon 4, was performed using a polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method [<a href="#b13" rid=
"b13" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252377">13</a>]. <em>CYP2C19</em> genotype analysis
revealed five different patterns as follows:
*<em>1/</em>*<em>1</em> in six; *<em>1/</em>*<em>2</em> in three;
*<em>1/</em>*<em>3</em> in three; *<em>2/</em>*<em>2</em> in five
and *<em>2/</em>*<em>3</em> in one patient. Subjects with these
genotype patterns were divided into three groups: the homEMs
(*<em>1/</em>*<em>1</em>, <em>n</em> = 6), the hetEMs
(*<em>1/</em>*<em>2</em> and *<em>1/</em>*<em>3</em>, <em>n</em> =
6) and the PMs (*<em>2/</em>*<em>2</em> and
*<em>2/</em>*<em>3</em>, <em>n</em> = 6).</p>
</div>
<div id="__sec10" class="sec">
<h3>Analysis of lansoprazole enantiomers and their metabolites in
plasma</h3>
<p id="__p11" class="p p-first-last">The plasma concentrations of
lansoprazole enantiomers and lansoprazole sulphone were determined
by HPLC with solid-phase extraction method of Miura <em>et
al</em>.[<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308926663">14</a>]. The HPLC column used was a Chiral CD-Ph
(250 mm × 4.6 mm I.D., Shiseido Co. Ltd, Tokyo, Japan). The mobile
phase consisted of 0.5 <span class="small-caps">m</span>
NaClO<sub>4</sub> : acetonitrile : methanol (60 : 30 : 10, v : v).
A flow rate of 0.5 ml min<sup>−1</sup> was used at ambient
temperature, and the wavelength was set at 285 nm. The lower limit
of quantification for this assay was 10 ng ml<sup>−1</sup> for
lansoprazole enantiomers and 5 ng ml<sup>−1</sup> for lansoprazole
sulphone. The coefficient of variation of inter- and intraday
assays (<em>n</em> = 6) was less than 8.0% and the accuracy
(<em>n</em> = 6) was within 8.4% for all analytes (concentration
range of 10–4000 ng ml<sup>−1</sup>).</p>
</div>
<div id="__sec11" class="sec">
<h3>Pharmacokinetic analysis</h3>
<p id="__p12" class="p p-first-last">Pharmacokinetic analysis of
the lansoprazole enantiomers and lansoprazole sulphone was carried
out by a standard noncompartmental method using WinNonlin
(Pharsight Co., CA, version 4.0.1). The elimination half-life was
obtained by log-linear regression of the terminal phase of the
concentration-time data for at least three sampling points
(elimination half-life = ln2/λ<sub>z</sub> where λ<sub>z</sub> =
elimination rate constant). The total area under the observed
plasma concentration-time curve (AUC) was calculated using the
linear trapezoidal rule. Extrapolation of AUC from the last
measurable concentration (<em>C</em><sub><em>t</em></sub>) to
infinity (AUC(<em>t</em>, ∞)) was performed by adding the value
<em>C</em><sub><em>t</em></sub>/λ<sub>z</sub> (where
<em>C</em><sub><em>t</em></sub> = plasma concentration at
<em>t</em> h after lansoprazole administration). The maximum plasma
concentration (<em>C</em><sub>max</sub>) and time required to reach
the peak (<em>t</em><sub>max</sub>) were directly obtained from the
profile.</p>
</div>
<div id="__sec12" class="sec sec-last">
<h3>Statistical analysis</h3>
<p id="__p13" class="p p-first-last">All results were expressed as
mean values ± SD and 95% confidence intervals (CI). Statistical
comparisons of the parameters were supplemented with the multiple
comparison procedure of Fisher using the Stat View program (SAS
Institute, Cary, NC, version 5.0). A <em>P</em> value of less than
0.05 was considered to be statistically significant.</p>
</div>
</div>
<div id="__sec13" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec13title">Results</h2>
<p id="__p14" class="p p-first">The mean plasma concentrations of
the (R)- and (S)-enantiomers of lansoprazole were significantly
increased by fluvoxamine in the three different <em>CYP2C19</em>
genotype groups (<a href="/pmc/articles/PMC1884909/figure/fig01/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1</span></a>). The plasma concentration-time profile of (R)- and
(S)-lansoprazole in the presence of fluvoxamine was similar among
the three <em>CYP2C19</em> genotype groups. Fluvoxamine
significantly increased the AUC(0, ∞) and <em>C</em><sub>max</sub>
and prolonged the elimination half-life of both (R)- and
(S)-lansoprazole in the homEMs and hetEMs, whereas in the PMs there
were no statistically significant differences in pharmacokinetic
parameters for the subjects given placebo and those given
fluvoxamine (<a href="/pmc/articles/PMC1884909/table/tbl1/" target=
"true" class="fig-table-link table figpopup" rid-figpopup="tbl1"
rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>), with
the exception of the AUC(0, ∞) of (R)-lansoprazole where a
significant difference was seen. The mean AUC(0, ∞) of (R)- and
(S)-lansoprazole in the homEMs fluvoxamine group was 2.2- and
1.9-fold higher, respectively, than the those in the PMs who did
not take fluvoxamine (45032 (28 786, 61 278) <em>vs</em> 20 132 (17
275, 22 989), 7322 (3354, 11 290) <em>vs</em> 3892 (3098, 4686) ng
ml<sup>−1</sup> h) (<a href="/pmc/articles/PMC1884909/table/tbl1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>).
The mean lansoprazole R/S ratio for the AUC(0, ∞) in the homEMs
differed significantly between the placebo and the fluvoxamine
treatment groups (12.7 (9.1, 16.8) <em>vs</em> 6.4 (5.4, 7.4),
respectively, <em>P</em> &lt; 0.0001), though not in the PMs (5.5
(4.3, 6.7) <em>vs</em> 5.9 (5.3, 6.5), respectively).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884909/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884909/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>The effect of fluvoxamine on the disposition of
(R)-lansoprazole (upper panel) and (S)-lansoprazole (lower panel)
in homozygous EMs (A), heterozygous EMs (B) and PMs (C). Subjects
received a single oral dose of 60 mg of racemic lansoprazole
following</span> <strong>...</strong></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC1884909/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC1884909/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC1884909/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884909/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span><!--caption a8--><strong>Pharmacokinetic parameters of
lansoprazole enantiomers with fluvoxamine in three CYP2C19 genotype
groups</strong></span></div>
</div>
</div>
<p id="__p16">The mean fluvoxamine induced percent increase in the
AUC(0, ∞) of (R)-lansoprazole in the homEMs compared with the PMs
was significant (<em>P =</em> 0.0117), although no differences were
observed in <em>C</em><sub>max</sub> among the three
<em>CYP2C19</em> genotypes. In contrast, fluvoxamine cased a
significant percent increase in both the AUC(0, ∞) and
<em>C</em><sub>max</sub> for (S)-lansoprazole in the homEMs
compared with the hetEMs (<em>P</em> = 0.0007 and <em>P</em> =
0.0125, respectively) and compared with the PMs (<em>P</em> &lt;
0.0001 for each parameter) (<a href=
"/pmc/articles/PMC1884909/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
The influence of fluvoxamine on the CYP2C19-mediated metabolism of
(S)-lansoprazole was much greater than that of the (R)-enantiomer
(<a href="/pmc/articles/PMC1884909/figure/fig02/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure
2</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884909/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884909/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>The change in AUC(0, ∞) and <em>C</em><sub>max</sub> of
(R)-lansoprazole (solid bars) and (S)-lansoprazole (open bars) by
fluvoxamine among the three <em>CYP2C19</em> genotype groups. Error
bars indicate SD</span></div>
</div>
</div>
<p id="__p18" class="p">Meanwhile, fluvoxamine increased the mean
plasma concentration of lansoprazole sulphone in the homEMs and
hetEMs, whereas concentrations in the PMs were slightly decreased
(<a href="/pmc/articles/PMC1884909/figure/fig03/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a> and
<a href="/pmc/articles/PMC1884909/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1884909/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC1884909/bin/bcp0060-0061-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884909/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>The influence of fluvoxamine on the formation of
lansoprazole sulphone in homozygous EMs (A), heterozygous EMs (B)
and PMs (C). Subjects received a single oral dose of 60 mg of
racemic lansoprazole following administration of placebo (○) or
25</span> <strong>...</strong></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC1884909/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC1884909/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC1884909/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1884909/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span><!--caption a8--><strong>Pharmacokinetic parameters of
lansoprazole sulphone with fluvoxamine in three CYP2C19 genotype
groups</strong></span></div>
</div>
</div>
</div>
<div id="__sec14" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec14title">Discussion</h2>
<p id="__p20" class="p p-first">This is the first report on the
effect of fluvoxamine, a CYP2C19 inhibitor, on the pharmacokinetics
of lansoprazole enantiomers in relation to <em>CYP2C19</em>
genotype status. The effect of fluvoxamine on lansoprazole
metabolism is greatest in individuals who are homEMs, less in
hetEMs and least in PMs of CYP2C19. In the present study,
fluvoxamine significantly increased the AUC(0, ∞) for (R)- and
(S)-lansoprazole in the homEMs by 903% and 1664%, respectively, and
in the hetEMs by 462% and 781%, respectively (<a href=
"/pmc/articles/PMC1884909/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
Thus, the drug interaction is more marked between (S)-lansoprazole
and fluvoxamine than between (R)-lansoprazole and fluvoxamine.
Furthermore, mean R : S ratios of AUC(0, ∞) for lansoprazole in the
presence of fluvoxamine were not significantly different between
homEMs and PMs (6.4 <em>vs</em> 5.9), although in the placebo
groups the ratio was significantly greater in the homEMs than in
the PMs (12.7 <em>vs</em> 5.5, <em>P</em> &lt; 0.05). These data
show that the magnitude of the contribution of CYP2C19 to the
metabolism of (S)-lansoprazole is much greater compared with that
of the (R)-enantiomer. This finding is supported by previous <em>in
vitro</em> data that describe a higher affinity and intrinsic
clearance for CYP2C19-catalyzed hydroxylation of (S)-lansoprazole
than of the (R)-enantiomer [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252391">8</a>]. In contrast (S)-omeprazole is less
influenced by CYP2C19 genetic polymorphism compared with
(R)-omeprazole and racemic omeprazole [<a href="#b15" rid="b15"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252394">15</a>–<a href="#b17" rid="b17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252379">17</a>]. This finding has led to the development
of esomeprazole, an (S)-enantiomer of omeprazole, as the first
single enantiomer PPI. Thus, the racemate is not simply a mixture
of the two enantiomers but rather a distinct molecular compound or
entity with properties quite distinct from those of the two optical
isomers [<a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252382">18</a>–<a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252390">22</a>]. Although the clinical relevance on the
effect of each enantiomer is not yet fully established, the
pharmacological activities of (R)- and (S)-lansoprazole according
to data obtained from <em>in vitro</em> studies are considered to
be similar [<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252387">23</a>]. The disposition of (R)-lansoprazole
appears to be less influenced by CYP2C19 than that of the
(S)-enantiomer. Therefore, the use of only (R)-lansoprazole would
be highly desirable for clinical application.</p>
<p id="__p21">In this study, we were unable to evaluate the
pharmacokinetic parameters of 5-hydroxylansoprazole enantiomers in
the plasma samples obtained from each subject co-administered
fluvoxamine, because the plasma concentrations of the enantiomers
were below the limit of detection by the HPLC method we used (lower
limit of quantification, 10 ng ml<sup>–l</sup> each) [<a href=
"#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308926664">14</a>]. However, fluvoxamine inhibits
5-hydroxylation of lansoprazole and consequently significantly
slows its elimination in the EMs. Fluvoxamine markedly increased
<em>C</em><sub>max</sub> and significantly prolonged the
elimination half-life of lansoprazole, particularly the
(S)-enantiomer; it seems that fluvoxamine inhibits the
biotransformation of lansoprazole during both the absorption and
elimination phases in the liver. Due to the inhibition of CYP2C19
activity by fluvoxamine, lansoprazole is preferentially metabolized
to lansoprazole sulphone by CYP3A4 in EMs, whereas in the PMs of
CYP2C19, fluvoxamine slightly inhibits the formation of
lansoprazole sulphone, though not significantly. This result
suggests that fluvoxamine inhibits CYP3A4 activity in PM subjects
to some extent [<a href="#b24" rid="b24" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252378">24</a>, <a href="#b25" rid="b25" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252396">25</a>], because lansoprazole sulphone is formed
solely by CYP3A4 [<a href="#b2" rid="b2" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137252376">2</a>,
<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_137252399">6</a>,
<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_137252389">7</a>].</p>
<p id="__p22" class="p p-last">In conclusion, the plasma
concentration of (S)-lansoprazole is considerably influenced by
fluvoxamine compared with that of the (<em>R</em>)-enantiomer. In
EMs subjects, hepatic CYP2C19 plays a more important role in the
absorption and elimination of (S)-lansoprazole compared with those
of the (R)-enantiomer.</p>
</div>
<div id="__ackid424675" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid424675title">
Acknowledgments</h2>
<div class="sec">
<p id="__p23">Competing interests: None declared.</p>
</div>
</div>
<div id="__ref-listid424682" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid424682title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Nagaya H, Satoh H, Maki Y. Possible mechanism for the
inhibition of acid formation by the proton pump inhibitor AG-1749
in isolated canine parietal cells. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1990;<span class=
"ref-vol">252</span>:1289–92.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2156997" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A.
Identification of the human P450 enzymes involved in lansoprazole
metabolism. <span><span class="ref-journal">J Pharmacol Exp
Ther.</span> 1996;<span class="ref-vol">277</span>:805–16.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/8627562" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M.
Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics
in Japanese subjects. <span><span class="ref-journal">Eur J Clin
Pharmacol.</span> 1997;<span class=
"ref-vol">52</span>:391–6.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9272410" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E,
Domerque J, Joyeux H, Cosme J, Guengerich FP. Oxidative metabolism
of lansoprazole by human liver cytochromes P450. <span><span class=
"ref-journal">Mol Pharmacol.</span> 1995;<span class=
"ref-vol">47</span>:410–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7870052" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Ishizaki T, Horai Y. Review article: cytochrome P450 and
the metabolism of proton pump inhibitors – emphasis on rabeprazole.
<span><span class="ref-journal">Aliment Pharmacol Ther.</span>
1999;<span class="ref-vol">13</span>:27–36.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10491726" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic
disposition of lansoprazole in relation to the S-mephenytoin
4′-hydroxylation phenotype status. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1997;<span class=
"ref-vol">61</span>:574–82.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9164419" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim
MK, Cha IJ, Hyun MH, Shin JG. Enantioselective disposition of
lansoprazole in extensive and poor metabolizers of CYP2C19.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2002;<span class="ref-vol">72</span>:90–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12152007" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu
KH, Chun JH, Hyun MH, Shin JG. Stereoselective metabolism of
lansoprazole by human liver cytochrome P450 enzymes.
<span><span class="ref-journal">Drug Metab Dispos.</span>
2003;<span class="ref-vol">31</span>:1227–34.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12975331" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M.
Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of
lansoprazole by human liver microsomes. <span><span class=
"ref-journal">Eur J Clin Pharmacol.</span> 2001;<span class=
"ref-vol">57</span>:709–15.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11829200" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE,
Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6
by citalopram, fluoxetine, fluvoxamine and paroxetine.
<span><span class="ref-journal">Eur J Clin Pharmacol.</span>
1996;<span class="ref-vol">51</span>:73–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8880055" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH.
Comparison of in vitro and in vivo inhibition potencies of
fluvoxamine toward CYP2C19. <span><span class="ref-journal">Drug
Metab Dispos.</span> 2003;<span class=
"ref-vol">31</span>:565–71.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12695344" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K,
Tateishi T, Suzuki T. Pharmacokinetic differences between the
enantiomers of lansoprazole and its metabolite,
5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
<span><span class="ref-journal">Eur J Clin Pharmacol.</span>
2004;<span class="ref-vol">60</span>:623–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15448955" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA,
Nakamura K, Goldstein JA. Identification of a new genetic defect
responsible for the polymorphism of (<em>S</em>)-mephenytoin
metabolism in Japanese. <span><span class="ref-journal">Mol
Pharmacol.</span> 1994;<span class=
"ref-vol">46</span>:594–5.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7969038" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Miura M, Tada H, Suzuki T. Simultaneous determination of
lansoprazole enantiomers and their metabolites in plasma by liquid
chromatography with solid–phase extraction. <span><span class=
"ref-journal">J Chromatogr B.</span> 2004;<span class=
"ref-vol">804</span>:389–95.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15081934" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Kanazawa H, Okada A, Higaki M, Yokota H, Mashige F,
Nakahara K. Stereospecific analysis of omeprazole in human plasma
as a probe for CYP2C19 phenotype. <span><span class="ref-journal">J
Pharm Biomed Anal.</span> 2003;<span class=
"ref-vol">30</span>:1817–24.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12485723" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">Tybring G, Bottiger Y, Widen J, Bertilsson L.
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19
in Swedish white subjects. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 1997;<span class=
"ref-vol">62</span>:129–37.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9284848" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Andersson T, Hassan-Alin M, Hasselgren G, Rohss K,
Weidolf L. Pharmacokinetic studies with esomeprazole, the
(S)–isomer of omeprazole. <span><span class="ref-journal">Clin
Pharmacokinet.</span> 2001;<span class=
"ref-vol">40</span>:411–6.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11475467" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">Howe R, Shanks RG. Optical isomers of propranolol.
<span><span class="ref-journal">Nature.</span> 1966;<span class=
"ref-vol">210</span>:1336–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/5963764" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Blaschke G, Kraft HP, Fickentscher K, Kohler F.
Chromatographic separation of racemic thalidomide and teratogenic
activity of its enantiomers. <span><span class=
"ref-journal">Arzneimittelforschung.</span> 1979;<span class=
"ref-vol">29</span>:1640–2.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/583234" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Hutt AJ, Tan SC. Drug chirality and its clinical
significance. <span><span class="ref-journal">Drugs.</span>
1996;<span class="ref-vol">52</span>:1–12.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8922553" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects
of drug action and disposition: therapeutic pitfalls.
<span><span class="ref-journal">J Pharm Sci.</span>
1989;<span class="ref-vol">78</span>:695–715.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2685226" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"citation">Walle T. Stereochemistry of the in vivo disposition and
metabolism of propranolol in dog and man using deuterium–labeled
pseudoracemates. <span><span class="ref-journal">Drug Metab
Dispos.</span> 1985;<span class="ref-vol">13</span>:279–82.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/2861983" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"citation">Nagaya H, Inatomi N, Nohara A, Satoh H. Effects of the
enantiomers of lansoprazole (AG−1749 on
(H<sup>+</sup>+K<sup>+</sup>)–ATPase activity in canine gastric
microsomes and acid formation in isolated canine parietal cells.
<span><span class="ref-journal">Biochem Pharmacol.</span>
1991;<span class="ref-vol">42</span>:1875–8.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1660270" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"citation">Suzuki Y, Shioiri T, Muratake T, Kawashima Y, Sato S,
Hagiwara M, Inoue Y, Shimoda K, Someya T. Effects of concomitant
fluvoxamine on the metabolism of alprazolam in Japanese psychiatric
patients: interaction with CYP2C19 mutated alleles.
<span><span class="ref-journal">Eur J Clin Pharmacol.</span>
2003;<span class="ref-vol">58</span>:829–33.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12698310" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"citation">Hemeryck A, Belpaire FM. Selective serotonin reuptake
inhibitors and cytochrome P−450 mediated drug–drug interactions: an
update. <span><span class="ref-journal">Curr Drug Metab.</span>
2002;<span class="ref-vol">3</span>:13–37.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11876575" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1884909&amp;issue-id=144695&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1884909/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1884909/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1884909/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1884909/pdf/bcp0060-0061.pdf">PDF
(211K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1884909" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884909%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884909%2F&amp;text=Enantioselective%20disposition%20of%20lansoprazole%20in%20relation%20to%20CYP2C19%20genotypes%20in%20the%20presence%20of%20fluvoxamine">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884909%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="15963095" data-aiid="1884909"
data-aid="1884909" data-iid="144695" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC1884909" data-md5=
"b5f31241059cc7288ebb8bef9c54097d"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc201">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1884909/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FB704F6FE7D821_0105SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
